Compare iShares MSCI Australia ETF (EWA) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Gilead Sciences, Inc. — how do they compare? iShares MSCI Australia ETF trades at $28.59, while Gilead Sciences, Inc. trades at $135.72 (market cap $163.51B). The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while iShares MSCI Australia ETF pays none, and iShares MSCI Australia ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| EWA | GILD | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.26 | $155.80 |
52-Week Low | $24.95 | $108.22 |
Market Cap | — | $163.51B |
Enterprise Value | — | $178.05B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA trades at $28.625, down 0.3% with a bullish technical signal from moving averages. The stock shows neutral oscillator readings with RSI at 72.02 suggesting potential overbought conditions. Recent news highlights Australia's economic developments including fuel excise relief and tax reforms that may impact investor sentiment toward Australian-focused assets.
The outlook remains cautiously optimistic given the bullish technical setup, though limited fundamental data availability requires careful monitoring. Key risks include Australian economic sensitivity and market volatility from geopolitical tensions. Investors should await updated financial metrics for comprehensive fundamental assessment.
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
